A multicenter, double-blind, randomized, placebo-controlled, parallel-group study evaluating the efficacy and safety of grass (Phleum pratense) sublingual tablet (SCH 697243) in adult subjects with a history of grass pollen induced rhinoconjunctivitis with or without asthma.

Trial Profile

A multicenter, double-blind, randomized, placebo-controlled, parallel-group study evaluating the efficacy and safety of grass (Phleum pratense) sublingual tablet (SCH 697243) in adult subjects with a history of grass pollen induced rhinoconjunctivitis with or without asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck
  • Most Recent Events

    • 02 Nov 2009 Primary endpoint 'Additional treatment required rescue medication' has been met.
    • 02 Nov 2009 Primary endpoint 'Symptom score' has been met.
    • 15 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top